San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
